Search

Your search keyword '"Blondeaux E"' showing total 146 results
Start Over Author "Blondeaux E"
146 results on '"Blondeaux E"'

1. Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology

Author

Agostinetto, E., Bruzzone, M., Hamy, A.-S., Kim, H.J., Chiodi, C., Bernstein-Molho, R., Linn, S., Pogoda, K., Carrasco, E., Derouane, F., Bajpai, J., Nader-Marta, G., Lopetegui-Lia, N., Partridge, A.H., Cortesi, L., Rousset-Jablonski, C., Giugliano, F., Renaud, T., Ferrari, A., Paluch-Shimon, S., Fruscio, R., Cui, W., Wong, S.M., Vernieri, C., Ruddy, K.J., Dieci, M.V., Matikas, A., Rozenblit, M., Aguilar y Mendez, D., De Marchis, L., Borea, R., Puglisi, F., Pistelli, M., Kufel-Grabowska, J., Di Rocco, R., Mariamidze, E., Atzori, F., Kourie, H.R., Popovic, L., de Azambuja, E., Blondeaux, E., and Lambertini, M.

Published
2024
Full Text
View/download PDF

2. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Author

Arecco, L., Bruzzone, M., Bas, R., Kim, H.J., Di Meglio, A., Bernstein-Molho, R., Hilbers, F.S., Pogoda, K., Carrasco, E., Punie, K., Bajpai, J., Agostinetto, E., Lopetegui-Lia, N., Partridge, A.H., Phillips, K.A., Toss, A., Rousset-Jablonski, C., Curigliano, G., Renaud, T., Ferrari, A., Paluch-Shimon, S., Fruscio, R., Cui, W., Wong, S.M., Vernieri, C., Couch, F.J., Dieci, M.V., Matikas, A., Rozenblit, M., Aguilar-y Méndez, D., De Marchis, L., Puglisi, F., Fabi, A., Graff, S.L., Witzel, I., Rodriguez Hernandez, A., Fontana, A., Pesce, R., Duchnowska, R., Pais, H.L., Sini, V., Sokolović, E., de Azambuja, E., Ceppi, M., Blondeaux, E., and Lambertini, M.

Published
2024
Full Text
View/download PDF

3. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

Author

Poggio, F., Blondeaux, E., Tagliamento, M., Perachino, M., Nardin, S., Conte, B., Giuliano, M., Arpino, G., De Laurentiis, M., Gravina, A., Bisagni, G., Rimanti, A., Turletti, A., Nisticò, C., Magnolfi, E., Gasparro, S., Fabi, A., Garrone, O., Alicicco, M.G., Urracci, Y., Poletti, P., Correale, P., Molinelli, C., Fozza, A., Puglisi, F., Colantuoni, G., Fregatti, P., Boni, L., Lambertini, M., and Del Mastro, L.

Published
2024
Full Text
View/download PDF

4. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis

Author

Arecco, L., Blondeaux, E., Bruzzone, M., Latocca, M.M., Mariamidze, E., Begijanashvili, S., Sokolovic, E., Gentile, G., Scavone, G., Ottonello, S., Boutros, A., Vaz-Luis, I., Saura, C., Anderson, R.A., Demeestere, I., Azim, H.A., Jr, de Azambuja, E., Peccatori, F.A., Del Mastro, L., Partridge, A.H., and Lambertini, M.

Published
2023
Full Text
View/download PDF

6. Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Author

Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, H, Di Meglio, A, Bernstein Molho, R, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lopetegui-Lia, N, Phillips, K, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Puglisi, F, Vasconcelos de Matos, L, Marino, M, Teixeira, L, Graffeo, R, Rognone, A, Chirco, A, Antone, N, Abdou, Y, Marhold, M, Bozovic-Spasojevic, I, Cortes Salgado, A, Carmisciano, L, Bruzzone, M, Curigliano, G, Prat, A, Lambertini, M, Schettini F., Blondeaux E., Molinelli C., Bas R., Kim H. J., Di Meglio A., Bernstein Molho R., Linn S. C., Pogoda K., Carrasco E., Punie K., Agostinetto E., Lopetegui-Lia N., Phillips K. -A., Toss A., Rousset-Jablonski C., Acheritogaray M., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Puglisi F., Vasconcelos de Matos L., Marino M., Teixeira L., Graffeo R., Rognone A., Chirco A., Antone N., Abdou Y., Marhold M., Bozovic-Spasojevic I., Cortes Salgado A., Carmisciano L., Bruzzone M., Curigliano G., Prat A., Lambertini M., Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, H, Di Meglio, A, Bernstein Molho, R, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lopetegui-Lia, N, Phillips, K, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Puglisi, F, Vasconcelos de Matos, L, Marino, M, Teixeira, L, Graffeo, R, Rognone, A, Chirco, A, Antone, N, Abdou, Y, Marhold, M, Bozovic-Spasojevic, I, Cortes Salgado, A, Carmisciano, L, Bruzzone, M, Curigliano, G, Prat, A, Lambertini, M, Schettini F., Blondeaux E., Molinelli C., Bas R., Kim H. J., Di Meglio A., Bernstein Molho R., Linn S. C., Pogoda K., Carrasco E., Punie K., Agostinetto E., Lopetegui-Lia N., Phillips K. -A., Toss A., Rousset-Jablonski C., Acheritogaray M., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Puglisi F., Vasconcelos de Matos L., Marino M., Teixeira L., Graffeo R., Rognone A., Chirco A., Antone N., Abdou Y., Marhold M., Bozovic-Spasojevic I., Cortes Salgado A., Carmisciano L., Bruzzone M., Curigliano G., Prat A., and Lambertini M.

Abstract

Background: Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)-low-expressing BC has recently emerged as a novel therapeutic target but has not been characterized in this rare patient subset. Methods: Women aged ≤40 years with newly diagnosed early-stage HER2-negative BC (HER2-0 and HER2-low) and germline BRCA1/2 PVs from 78 health care centers worldwide were retrospectively included. Chi-square test and Student t-test were used to describe variable distribution between HER2-0 and HER2-low. Associations with HER2-low status were assessed with logistic regression. Kaplan–Meier method and Cox regression analysis were used to assess disease-free survival (DFS) and overall survival. Statistical significance was considered for p ≤.05. Results: Of 3547 included patients, 32.3% had HER2-low BC, representing 46.3% of hormone receptor–positive and 21.3% of triple-negative (TN) tumors. HER2-low vs. HER2-0 BC were more often of grade 1/2 (p <.001), hormone receptor–positive (p <.001), and node-positive (p =.003). BRCA2 PVs were more often associated with HER2-low than BRCA1 PVs (p <.001). HER2-low versus HER2-0 showed better DFS (hazard ratio [HR], 0.86; 95% CI, 0.76–0.97) in the overall population and more favorable DFS (HR, 0.78; 95% CI, 0.64–0.95) and overall survival (HR, 0.65; 95% CI, 0.46–0.93) in the TN subgroup. Luminal A–like tumors in HER2-low (p =.014) and TN and luminal A-like in HER2-0 (p =.019) showed the worst DFS. Conclusions: In young patients with HER2-negative BC and germline BRCA1/2 PVs, HER2-low disease was less frequent than expected and more frequently linked to BRCA2 PVs and associated with luminal-like disease. HER2-low status was associated with a modestly improved prognosis.

Published
2024

7. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study

Author

Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., Partridge A. H., Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., and Partridge A. H.

Abstract

(Abstracted from JAMA 2024;331(1):49-59 Individuals who are diagnosed with breast cancer at a young age are often carriers of a pathogenic variant in the BRCA1 or BRCA2 genes, and many young women in this situation are interested in preserving future fertility, if possible. Reproductive counseling in this situation can be complex due to the risk of passing on the variant, as well as the implications on their own fertility, as the mutation can impact ovarian reserve, fertility potential, and other factors.

Published
2024

8. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Author

Arecco, L, Bruzzone, M, Bas, R, Kim, H, Di Meglio, A, Bernstein-Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Agostinetto, E, Lopetegui-Lia, N, Partridge, A, Phillips, K, Toss, A, Rousset-Jablonski, C, Curigliano, G, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Couch, F, Dieci, M, Matikas, A, Rozenblit, M, Aguilar-y Mendez, D, De Marchis, L, Puglisi, F, Fabi, A, Graff, S, Witzel, I, Rodriguez Hernandez, A, Fontana, A, Pesce, R, Duchnowska, R, Pais, H, Sini, V, Sokolovic, E, de Azambuja, E, Ceppi, M, Blondeaux, E, Lambertini, M, Arecco L., Bruzzone M., Bas R., Kim H. J., Di Meglio A., Bernstein-Molho R., Hilbers F. S., Pogoda K., Carrasco E., Punie K., Bajpai J., Agostinetto E., Lopetegui-Lia N., Partridge A. H., Phillips K. A., Toss A., Rousset-Jablonski C., Curigliano G., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Couch F. J., Dieci M. V., Matikas A., Rozenblit M., Aguilar-y Mendez D., De Marchis L., Puglisi F., Fabi A., Graff S. L., Witzel I., Rodriguez Hernandez A., Fontana A., Pesce R., Duchnowska R., Pais H. L., Sini V., Sokolovic E., de Azambuja E., Ceppi M., Blondeaux E., Lambertini M., Arecco, L, Bruzzone, M, Bas, R, Kim, H, Di Meglio, A, Bernstein-Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Agostinetto, E, Lopetegui-Lia, N, Partridge, A, Phillips, K, Toss, A, Rousset-Jablonski, C, Curigliano, G, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Couch, F, Dieci, M, Matikas, A, Rozenblit, M, Aguilar-y Mendez, D, De Marchis, L, Puglisi, F, Fabi, A, Graff, S, Witzel, I, Rodriguez Hernandez, A, Fontana, A, Pesce, R, Duchnowska, R, Pais, H, Sini, V, Sokolovic, E, de Azambuja, E, Ceppi, M, Blondeaux, E, Lambertini, M, Arecco L., Bruzzone M., Bas R., Kim H. J., Di Meglio A., Bernstein-Molho R., Hilbers F. S., Pogoda K., Carrasco E., Punie K., Bajpai J., Agostinetto E., Lopetegui-Lia N., Partridge A. H., Phillips K. A., Toss A., Rousset-Jablonski C., Curigliano G., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Couch F. J., Dieci M. V., Matikas A., Rozenblit M., Aguilar-y Mendez D., De Marchis L., Puglisi F., Fabi A., Graff S. L., Witzel I., Rodriguez Hernandez A., Fontana A., Pesce R., Duchnowska R., Pais H. L., Sini V., Sokolovic E., de Azambuja E., Ceppi M., Blondeaux E., and Lambertini M.

Abstract

Background: Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its prognostic impact on prognosis of young patients harboring a pathogenic variant (PV) in the BRCA1 and/or BRCA2 genes. Patients and methods: This international, multicenter, retrospective cohort study included young patients (aged ≤40 years) diagnosed with invasive breast cancer and harboring germline PVs in BRCA genes. We investigated the impact of hormone receptor status on clinical behavior and outcomes of breast cancer. Outcomes of interest [disease-free survival (DFS), breast cancer-specific survival (BCSS), and overall survival (OS)] were first investigated according to hormone receptor expression (positive versus negative), and then according to breast cancer subtype [luminal A-like versus luminal B-like versus triple-negative versus human epidermal growth factor receptor 2 (HER2)-positive breast cancer]. Results: From 78 centers worldwide, 4709 BRCA carriers were included, of whom 2143 (45.5%) had hormone receptor-positive and 2566 (54.5%) hormone receptor-negative breast cancer. Median follow-up was 7.9 years. The rate of distant recurrences was higher in patients with hormone receptor-positive disease (13.1% versus 9.6%, P < 0.001), while the rate of second primary breast cancer was lower (9.1% versus 14.7%, P < 0.001) compared to patients with hormone receptor-negative disease. The 8-year DFS was 65.8% and 63.4% in patients with hormone receptor-positive and negative disease, respectively. The hazard ratio of hormone receptor-positive versus negative disease changed over time for DFS, BCSS, and OS (P < 0.05 for interaction of hormone receptor status and survival time). Patients with luminal A-like breast cancer had the worst long-term prognosis in terms of DFS compared to all the other subgroups (8-year DFS: 60.8% in luminal A-like versus 63.5% in triple-negative versus 65.5% in HER2-positive and 69

Published
2024

9. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group

Author

Balic, Marija, Heibl, Sonja, Zabernigg, August Felix, Egle, Daniel, Sandholzer, Margit, Roitner, Florian, Andel, Johannes, Pichler, Petra, Hager, Christopher, Knauer, Michael, Hubalek, Michael, Bighin, Claudia, De Laurentiis, Michelino, De Placido, Sabino, Puglisi, Fabio, Boni, Luca, de Gregorio, Amelie, Degenhardt, Tom, Formisano, Luigi, Beelen, Karin, Robinson, Timothy, Fitzpatrick, Amanda, Dieras, Veronique, Muller, Volkmar, Gennari, Alessandra, Linn, Sabine, Braga, Sofia, Cortes, Javier, Palmieri, Carlo, Gampenrieder, S.P., Dezentjé, V., Lambertini, M., de Nonneville, A., Marhold, M., Le Du, F., Cortés Salgado, A., Alpuim Costa, D., Vaz Batista, M., Chic Ruché, N., Tinchon, C., Petzer, A., Blondeaux, E., Del Mastro, L., Targato, G., Bertucci, F., Gonçalves, A., Viret, F., Bartsch, R., Mannsbart, C., Deleuze, A., Robert, L., Saavedra Serrano, C., Gion Cortés, M., Sampaio-Alves, M., Vitorino, M., Pecen, L., Singer, C., Harbeck, N., Rinnerthaler, G., and Greil, R.

Published
2023
Full Text
View/download PDF

10. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Author

Condorelli, M., Bruzzone, M., Ceppi, M., Ferrari, A., Grinshpun, A., Hamy, A.S., de Azambuja, E., Carrasco, E., Peccatori, F.A., Di Meglio, A., Paluch-Shimon, S., Poorvu, P.D., Venturelli, M., Rousset-Jablonski, C., Senechal, C., Livraghi, L., Ponzone, R., De Marchis, L., Pogoda, K., Sonnenblick, A., Villarreal-Garza, C., Córdoba, O., Teixeira, L., Clatot, F., Punie, K., Graffeo, R., Dieci, M.V., Pérez-Fidalgo, J.A., Duhoux, F.P., Puglisi, F., Ferreira, A.R., Blondeaux, E., Peretz-Yablonski, T., Caron, O., Saule, C., Ameye, L., Balmaña, J., Partridge, A.H., Azim, H.A., Demeestere, I., and Lambertini, M.

Published
2021
Full Text
View/download PDF

11. Pregnancy After Breast Cancer in Young BRCA Carriers

Author

Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A-S, Kim, HJ, Di Meglio, A, Molho, RB, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, HCF, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Peccatori, FA, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, SM, Vernieri, C, Ruddy, KJ, Dieci, MV, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, MDP, Rodriguez-Wallberg, KA, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y-J, Maria, C, Azim, HA, Boni, L, Partridge, AH, Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A-S, Kim, HJ, Di Meglio, A, Molho, RB, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, HCF, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Peccatori, FA, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, SM, Vernieri, C, Ruddy, KJ, Dieci, MV, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, MDP, Rodriguez-Wallberg, KA, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y-J, Maria, C, Azim, HA, Boni, L, and Partridge, AH

Abstract

IMPORTANCE: Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy in breast cancer survivors included limited data regarding BRCA carriers. OBJECTIVE: To investigate cumulative incidence of pregnancy and disease-free survival in young women who are BRCA carriers. DESIGN, SETTING, AND PARTICIPANTS: International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The study included female participants diagnosed with invasive breast cancer at age 40 years or younger between January 2000 and December 2020 carrying germline pathogenic variants in BRCA1 and/or BRCA2. Last delivery was October 7, 2022; last follow-up was February 20, 2023. EXPOSURE: Pregnancy after breast cancer. MAIN OUTCOMES AND MEASURES: Primary end points were cumulative incidence of pregnancy after breast cancer and disease-free survival. Secondary end points were breast cancer-specific survival, overall survival, pregnancy, and fetal and obstetric outcomes. RESULTS: Of 4732 BRCA carriers included, 659 had at least 1 pregnancy after breast cancer and 4073 did not. Median age at diagnosis in the overall cohort was 35 years (IQR, 31-38 years). Cumulative incidence of pregnancy at 10 years was 22% (95% CI, 21%-24%), with a median time from breast cancer diagnosis to conception of 3.5 years (IQR, 2.2-5.3 years). Among the 659 patients who had a pregnancy, 45 (6.9%) and 63 (9.7%) had an induced abortion or a miscarriage, respectively. Of the 517 patients (79.7%) with a completed pregnancy, 406 (91.0%) delivered at term (≥37 weeks) and 54 (10.4%) had twins. Among the 470 infants born with known information on pregnancy complications, 4 (0.9%) had documented congenital anomalies. Median follow-up was 7.8 years (IQR, 4.5-12.6 years). No significant difference in disease-free survival was observed between patie

Published
2024

12. 163P Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Author

Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, HJ, Di Meglio, A, Molho, RB, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lia, NL, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Curigliano, G, Prat, A, Lambertini, M, Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, HJ, Di Meglio, A, Molho, RB, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lia, NL, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Curigliano, G, Prat, A, and Lambertini, M

Published
2024

13. 160P Characteristics and outcomes of young breast cancer patients harboring BRCA pathogenic variants according to histologic subtype

Author

Agostinetto, E, Bruzzone, M, Hamy-Petit, A-S, Kim, HJ, Chiodi, CK, Molho, RB, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Lia, NL, Partridge, AH, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Giugliano, F, de Azambuja, E, Blondeaux, E, Lambertini, M, Agostinetto, E, Bruzzone, M, Hamy-Petit, A-S, Kim, HJ, Chiodi, CK, Molho, RB, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Lia, NL, Partridge, AH, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Giugliano, F, de Azambuja, E, Blondeaux, E, and Lambertini, M

Published
2024

14. Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology

Author

Agostinetto, E, Bruzzone, M, Hamy, A, Kim, H, Chiodi, C, Bernstein-Molho, R, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Nader-Marta, G, Lopetegui-Lia, N, Partridge, A, Cortesi, L, Rousset-Jablonski, C, Giugliano, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Aguilar Y Mendez, D, De Marchis, L, Borea, R, Puglisi, F, Pistelli, M, Kufel-Grabowska, J, Di Rocco, R, Mariamidze, E, Atzori, F, Kourie, H, Popovic, L, de Azambuja, E, Blondeaux, E, Lambertini, M, Hamy, A-S, Kim, H J, Partridge, A H, Wong, S M, Ruddy, K J, Dieci, M V, Kourie, H R, Agostinetto, E, Bruzzone, M, Hamy, A, Kim, H, Chiodi, C, Bernstein-Molho, R, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Nader-Marta, G, Lopetegui-Lia, N, Partridge, A, Cortesi, L, Rousset-Jablonski, C, Giugliano, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Aguilar Y Mendez, D, De Marchis, L, Borea, R, Puglisi, F, Pistelli, M, Kufel-Grabowska, J, Di Rocco, R, Mariamidze, E, Atzori, F, Kourie, H, Popovic, L, de Azambuja, E, Blondeaux, E, Lambertini, M, Hamy, A-S, Kim, H J, Partridge, A H, Wong, S M, Ruddy, K J, Dieci, M V, and Kourie, H R

Abstract

Background: Young women with breast cancer (BC) have an increased chance of carrying germline BRCA pathogenic variants (PVs). Limited data exist on the prognostic impact of tumor histology (i.e. ductal versus lobular) in hereditary breast cancer. Methods: This multicenter retrospective cohort study included women aged ≤40 years with early-stage breast cancer diagnosed between January 2000 and December 2020 and known to carry germline PVs in BRCA1/2. Histology was locally assessed in each center. The Kaplan-Meier method and Cox regression analysis were used to assess disease-free survival and overall survival. Results: Of 4628 patients included from 78 centers worldwide, 3969 (86%) had pure ductal, 135 (3%) pure lobular, and 524 (11%) other histologies. Compared with ductal tumors, lobular tumors were more often grade 1/2 (57.7% versus 22.1%), stage III (29.6% versus 18.5%), and luminal A-like (42.2% versus 12.2%). Lobular tumors were more often associated with BRCA2 PVs (71.1% BRCA2), while ductal tumors were more often associated with BRCA1 PVs (65.7% BRCA1). Patients with lobular tumors more often had mastectomy (68.9% versus 58.3%), and less often received chemotherapy (83.7% versus 92.9%). With a median follow-up of 7.8 years, no significant differences were observed in disease-free survival (adjusted hazard ratio 1.01, 95% confidence interval 0.74-1.37) or overall survival (hazard ratio 0.96, 95% confidence interval 0.62-1.50) between patients with ductal versus lobular tumors. No significant survival differences were observed according to specific BRCA gene, breast cancer subtype, or body mass index. Conclusions: In this large global cohort of young BRCA carriers with breast cancer, the incidence of pure lobular histology was low and associated with higher disease stage at diagnosis, luminal-like disease and BRCA2 PVs. Histology did not appear to impact prognosis.

Published
2024

15. O-277 Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis

Author

Arecco, L, primary, Blondeaux, E, additional, Mariamidze, E, additional, Begijanashvili, S, additional, Sokolovic, E, additional, Scavone, G, additional, Ottonello, S, additional, Vaz-Luis, I, additional, Sàura, C, additional, Anderson, R A, additional, Demeestere, I, additional, Azim, H A, additional, Peccatori, F A, additional, Partridge, A H, additional, and Lambertini, M, additional

Published
2023
Full Text
View/download PDF

17. 101P Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: An individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, M., primary, Blondeaux, E., additional, Bisagni, G., additional, Mura, S., additional, de Placido, S., additional, De Laurentiis, M., additional, Fabi, A., additional, Rimanti, A., additional, Michelotti, A., additional, Mansutti, M., additional, Russo, A., additional, Montemurro, F., additional, Frassoldati, A., additional, Durando, A., additional, Gori, S., additional, Turletti, A., additional, Tamberi, S., additional, Urracci, Y., additional, de Azambuja, E., additional, and Del Mastro, L., additional

Published
2023
Full Text
View/download PDF

18. 276P Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis

Author

Arecco, L., primary, Blondeaux, E., additional, Bruzzone, M., additional, Latocca, M.M., additional, Mariamidze, E., additional, Begijanashvili, S., additional, Sokolovic, E., additional, Scavone, G., additional, Ottonello, S., additional, Boutros, A., additional, Luis, I.V. Vaz, additional, Manich, C. Saura, additional, Anderson, R.A., additional, Demeestere, I., additional, Azim, H.A., additional, de Azambuja, E., additional, Peccatori, F.A., additional, Del Mastro, L., additional, Partridge, A.H., additional, and Lambertini, M., additional

Published
2023
Full Text
View/download PDF

19. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group

Author

Gampenrieder, S.P., primary, Dezentjé, V., additional, Lambertini, M., additional, de Nonneville, A., additional, Marhold, M., additional, Le Du, F., additional, Cortés Salgado, A., additional, Alpuim Costa, D., additional, Vaz Batista, M., additional, Chic Ruché, N., additional, Tinchon, C., additional, Petzer, A., additional, Blondeaux, E., additional, Del Mastro, L., additional, Targato, G., additional, Bertucci, F., additional, Gonçalves, A., additional, Viret, F., additional, Bartsch, R., additional, Mannsbart, C., additional, Deleuze, A., additional, Robert, L., additional, Saavedra Serrano, C., additional, Gion Cortés, M., additional, Sampaio-Alves, M., additional, Vitorino, M., additional, Pecen, L., additional, Singer, C., additional, Harbeck, N., additional, Rinnerthaler, G., additional, Greil, R., additional, Balic, Marija, additional, Heibl, Sonja, additional, Zabernigg, August Felix, additional, Egle, Daniel, additional, Sandholzer, Margit, additional, Roitner, Florian, additional, Andel, Johannes, additional, Pichler, Petra, additional, Hager, Christopher, additional, Knauer, Michael, additional, Hubalek, Michael, additional, Bighin, Claudia, additional, De Laurentiis, Michelino, additional, De Placido, Sabino, additional, Puglisi, Fabio, additional, Boni, Luca, additional, de Gregorio, Amelie, additional, Degenhardt, Tom, additional, Formisano, Luigi, additional, Beelen, Karin, additional, Robinson, Timothy, additional, Fitzpatrick, Amanda, additional, Dieras, Veronique, additional, Muller, Volkmar, additional, Gennari, Alessandra, additional, Linn, Sabine, additional, Braga, Sofia, additional, Cortes, Javier, additional, and Palmieri, Carlo, additional

Published
2023
Full Text
View/download PDF

20. 1815O Breastfeeding after breast cancer in young BRCA carriers: Results from an international cohort study.

Author

Blondeaux, E., Delucchi, V., Mariamidze, E., Bernstein Molho, R., Hamy-Petit, A-S., Ferrari, A., Linn, S., Kim, H.J., Agostinetto, E., Paluch-Shimon, S., Toss, A., Di Meglio, A., Balmaña, J., Yerushalmi, R., Rodriguez-Wallberg, K.R., Demeestere, I., Azim, H.A., Peccatori, F.A., Partridge, A.H., and Lambertini, M.

Subjects
*BREAST cancer, *BRCA genes, *BREASTFEEDING, *COHORT analysis
Published
2024
Full Text
View/download PDF

21. 270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort

Author

Cucciniello, L., primary, Blondeaux, E., additional, Bighin, C., additional, Gasparro, M.S., additional, Russo, S., additional, Dri, A., additional, Pugliese, P., additional, Fontana, A., additional, Naso, G., additional, Ferzi, A., additional, Riccardi, F., additional, Sini, V., additional, Fabi, A., additional, Montemurro, F., additional, De Laurentiis, M., additional, Arpino, G., additional, Del Mastro, L., additional, Gerratana, L., additional, and Puglisi, F., additional

Published
2022
Full Text
View/download PDF

22. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)

Author

Del Mastro, L., primary, Poggio, F., additional, Blondeaux, E., additional, de Placido, S., additional, Giuliano, M., additional, De Laurentiis, M., additional, Bisagni, G., additional, Cantore, M., additional, Turletti, A., additional, Nisticò, C., additional, Urracci, Y., additional, Garrone, O., additional, Bighin, C., additional, Mansutti, M., additional, Montemurro, F., additional, Colantuoni, G., additional, Lambertini, M., additional, and Boni, L., additional

Published
2022
Full Text
View/download PDF

23. 243P Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials

Author

Arecco, L., Blondeaux, E., Bruzzone, M., Arpino, G., De Angelis, C., De Laurentiis, M., Caputo, R., Fabi, A., V. sanna, Gori, S., Puglisi, F., Boni, L., Nardin, S., Giannubilo, I., Perachino, M., Borea, R., Agostinetto, E., de Azambuja, E., Lambertini, M., and Del Mastro, L.

Published
2024
Full Text
View/download PDF

25. P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial

Author

Marrocco, C, primary, Conte, B, additional, Rossi, G, additional, Pirrone, C, additional, Favero, D, additional, Massarotti, C, additional, Anserini, P, additional, Fregatti, P, additional, Cardinali, B, additional, Buzzati, G, additional, Levaggi, A, additional, Poggio, F, additional, Blondeaux, E, additional, Del Mastro, L, additional, and Lambertini, M, additional

Published
2022
Full Text
View/download PDF

26. 113P Axillary lymph node management in early breast cancer patients with positive sentinel lymph node: A systematic review and meta-analysis of randomized trials

Author

Ruelle, T., primary, Perachino, M., additional, Blondeaux, E., additional, Bruzzone, M., additional, Fozza, A., additional, Garlaschi, A., additional, Belgioia, L., additional, Pitto, F., additional, Levaggi, A., additional, Sparavigna, M., additional, Del Mastro, L., additional, Lambertini, M., additional, and Fregatti, P., additional

Published
2022
Full Text
View/download PDF

27. 177P Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)

Author

Gampenrieder, S.P., primary, Dezentjé, V., additional, Lambertini, M., additional, de Nonneville, A., additional, Marhold, M., additional, Le Du, F., additional, Saavedra Serrano, C., additional, Alpuim Costa, D., additional, Blondeaux, E., additional, Del Mastro, L., additional, Bertucci, F., additional, Gonçalves, A., additional, Bartsch, R., additional, Deleuze, A., additional, Cortés Salgado, A., additional, Vitorino, M., additional, Tinchon, C., additional, Pecen, L., additional, Rinnerthaler, G., additional, and Greil, R., additional

Published
2022
Full Text
View/download PDF

28. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis

Author

Arecco, L, primary, Blondeaux, E, additional, Bruzzone, M, additional, Ceppi, M, additional, Latocca, M M, additional, Marrocco, C, additional, Boutros, A, additional, Spagnolo, F, additional, Razeti, M G, additional, Favero, D, additional, Spinaci, S, additional, Condorelli, M, additional, Massarotti, C, additional, Goldrat, O, additional, Del Mastro, L, additional, Demeestere, I, additional, and Lambertini, M, additional

Published
2022
Full Text
View/download PDF

30. 307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer

Author

Blondeaux, E., primary, Boni, L., additional, Ruelle, T., additional, Di Lauro, V., additional, Molinelli, C., additional, Piezzo, M., additional, Fratini, B., additional, Poggio, F., additional, Pugliese, P., additional, Ferzi, A., additional, Buzzatti, G., additional, Russo, S., additional, Garrone, O., additional, Gasparro, S., additional, D'Alonzo, A., additional, De Laurentiis, M., additional, Fabi, A., additional, Arpino, G., additional, Bighin, C., additional, and Del Mastro, L., additional

Published
2021
Full Text
View/download PDF

31. 261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes

Author

Cerbone, L., primary, Blondeaux, E., additional, Boni, L., additional, Ruelle, T., additional, Russo, S., additional, Bonotto, M., additional, Targato, G., additional, De Laurentiis, M., additional, Piezzo, M., additional, Arpino, G., additional, Pugliese, P., additional, Fabi, A., additional, D'Alonzo, A., additional, Giannubilo, I., additional, Conte, B., additional, Mulinelli, C., additional, Lambertini, M., additional, Bighin, C., additional, and Del Mastro, L., additional

Published
2021
Full Text
View/download PDF

32. Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico Del Nord Ovest) Study

Author

Garrone O, Giarratano T, Blondeaux E, Mastro LD, Santini D, D’Onofrio L, Michelotti A, Landucci E, Beano A, Aprile G, Guarneri V, Paccagnella M, Vanella P, Ruatta F, Denaro N, Saggia C, Coltelli L, Allegrini G, Cazzaniga ME, LaVerde N, Collovà E, Montemurro F, Blasi L, Ardito R, DeConciliis E, Airoldi M, and Merlano MC

Published
2021

33. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Condorelli, M, Bruzzone, M, Ceppi, M, Ferrari, A, Grinshpun, A, Hamy, A S, de Azambuja, E, Carrasco, E, Peccatori, F A, Di Meglio, A, Paluch-Shimon, S, Poorvu, P D, Venturelli, M, Rousset-Jablonski, C, Senechal, C, Livraghi, L, Ponzone, R, De Marchis, L, Pogoda, K, Sonnenblick, A, Villarreal-Garza, C, Córdoba, O, Teixeira, L, Clatot, F, Punie, K, Graffeo, R, Dieci, M V, Pérez-Fidalgo, J A, Duhoux, Francois, Puglisi, F, Ferreira, A R, Blondeaux, E, Peretz-Yablonski, T, Caron, O, Saule, C, Ameye, L, Balmaña, J, Partridge, A H, Azim, H A, Demeestere, I, Lambertini, M, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Condorelli, M, Bruzzone, M, Ceppi, M, Ferrari, A, Grinshpun, A, Hamy, A S, de Azambuja, E, Carrasco, E, Peccatori, F A, Di Meglio, A, Paluch-Shimon, S, Poorvu, P D, Venturelli, M, Rousset-Jablonski, C, Senechal, C, Livraghi, L, Ponzone, R, De Marchis, L, Pogoda, K, Sonnenblick, A, Villarreal-Garza, C, Córdoba, O, Teixeira, L, Clatot, F, Punie, K, Graffeo, R, Dieci, M V, Pérez-Fidalgo, J A, Duhoux, Francois, Puglisi, F, Ferreira, A R, Blondeaux, E, Peretz-Yablonski, T, Caron, O, Saule, C, Ameye, L, Balmaña, J, Partridge, A H, Azim, H A, Demeestere, I, and Lambertini, M

Abstract

Knowledge is growing on the safety of assisted reproductive techniques (ART) in cancer survivors. No data exist, however, for the specific population of breast cancer patients harboring germline BRCA1/2 pathogenic variants. This is a multicenter retrospective cohort study across 30 centers worldwide including women diagnosed at ≤40 years with stage I-III breast cancer, between January 2000 and December 2012, harboring known germline BRCA1/2 pathogenic variants. Patients included in this analysis had a post-treatment pregnancy either achieved through use of ART (ART group) or naturally (non-ART group). ART procedures included ovulation induction, ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection, and embryo transfer under hormonal replacement therapy. Among the 1424 patients registered in the study, 168 were eligible for inclusion in the present analysis, of whom 22 were in the ART group and 146 in the non-ART group. Survivors in the ART group conceived at an older age compared with those in the non-ART group (median age: 39.7 versus 35.4 years, respectively). Women in the ART group experienced more delivery complications compared with those in the non-ART group (22.1% versus 4.1%, respectively). No other apparent differences in obstetrical outcomes were observed between cohorts. The median follow-up from pregnancy was 3.4 years (range: 0.8-8.6 years) in the ART group and 5.0 years (range: 0.8-17.6 years) in the non-ART group. Two patients (9.1%) in the ART group experienced a disease-free survival event (specifically, a locoregional recurrence) compared with 40 patients (27.4%) in the non-ART group. In the ART group, no patients deceased compared with 10 patients (6.9%) in the non-ART group. This study provides encouraging safety data on the use of ART in breast cancer survivors harboring germline pathogenic variants in BRCA1/2, when natural conception fails or when they opt for ART in order to carry out preimplantation genetic testi

Published
2021

35. 290P From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial

Author

Garrone, O., primary, Giarratano, T., additional, Michelotti, A., additional, Saggia, C., additional, D'Onofrio, L., additional, Merlini, L., additional, Blondeaux, E., additional, Beano, A., additional, Coltelli, L., additional, Cazzaniga, M.E., additional, Montemurro, F., additional, Farnesi, A., additional, La Verde, N.M., additional, Vandone, A.M., additional, Collovà, E., additional, Blasi, L., additional, Ardito, R., additional, DeConciliis, E., additional, Airoldi, M., additional, and Merlano, M.C., additional

Published
2020
Full Text
View/download PDF

36. 226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study

Author

Molinelli, C., primary, Del Mastro, L., additional, Giraudi, S., additional, Ballestrero, A., additional, Carli, F., additional, Poggio, F., additional, D'Alonzo, A., additional, Dellepiane, C., additional, Buzzatti, G., additional, Blondeaux, E., additional, Conte, B., additional, Pastorino, S., additional, Gallo, M., additional, Lambertini, M., additional, and Bighin, C., additional

Published
2020
Full Text
View/download PDF

37. 3 Young Investigator Awardee - Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella (GIM) and Mammella Intergruppo trials (MIG).

Author

Blondeaux, E., Xie, W., Carmisciano, L., Mura, S., Sanna, V., De Laurentiis, M., Caputo, R., Turletti, A., Durando, A., De Angelis, C., Bisagni, G., Gasparini, E., Rimanti, A., Puglisi, F., Landucci, E., Fabi, A., Boni, L., Lambertini, M., Del Mastro, L., and Regan, M.M.

Subjects
*BREAST tumor treatment, *CONFERENCES & conventions, *AWARDS, *TUMOR classification
Published
2024
Full Text
View/download PDF

38. Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial

Author

Conte, B., primary, Bruzzone, M., additional, Lambertini, M., additional, Poggio, F., additional, Blondeaux, E., additional, De Laurentiis, M., additional, Valle, E., additional, Cognetti, F., additional, Nisticò, C., additional, De Placido, S., additional, Merlano, M.C., additional, Gamucci, T., additional, Montemurro, F., additional, Ceppi, M., additional, and Del Mastro, L., additional

Published
2019
Full Text
View/download PDF

40. Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab

Author

Conte, B., primary, Fabi, A., additional, Poggio, F., additional, Blondeaux, E., additional, Dellepiane, C., additional, D'Alonzo, A., additional, Staiano, A., additional, Buono, G., additional, Arpino, G., additional, Magri, V., additional, Naso, G., additional, Presti, D., additional, Mura, S., additional, Fontana, A., additional, Cognetti, F., additional, Molinelli, C., additional, Pastorino, S., additional, Bighin, C., additional, Lambertini, M., additional, and Del Mastro, L., additional

Published
2018
Full Text
View/download PDF

41. Abstract P5-21-29: Moving from the CLEOPATRA study to real life: Preliminary results from the G.O.N.O. SUPER trial

Author

Garrone, O, primary, D'Onofrio, L, additional, Blondeaux, E, additional, Bertolini, I, additional, Giarratano, T, additional, Beano, A, additional, Saggia, C, additional, Cazzaniga, M, additional, LaVerde, N, additional, Collovà, E, additional, Milani, A, additional, De Conciliis, E, additional, Coltelli, L, additional, Airoldi, M, additional, Del Mastro, L, additional, Cursano, MC, additional, Michelotti, A, additional, Vandone, AM, additional, Guarneri, V, additional, Donadio, M, additional, Riva, F, additional, Nuzzo, A, additional, and Merlano, MC, additional

Published
2018
Full Text
View/download PDF

42. Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

Author

D' Alonzo, A., primary, Bighin, C., additional, Puglisi, F., additional, Gerratana, L., additional, De Laurentis, M., additional, Fontana, A., additional, Pugliese, P., additional, Ferzi, A., additional, Montemurro, F., additional, Arpino, G., additional, Poggio, F., additional, Vaglica, M., additional, Dellepiane, C., additional, Blondeaux, E., additional, Benedetta, C., additional, Cognetti, F., additional, Garrone, O., additional, Turletti, A., additional, Pastorino, S., additional, and Del Mastro, L., additional

Published
2017
Full Text
View/download PDF

43. The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)

Author

Dellepiane, C., primary, Lambertini, M., additional, Fontana, V., additional, Poggio, F., additional, Blondeaux, E., additional, Conte, B., additional, D'Alonzo, A., additional, Vaglica, M., additional, Bighin, C., additional, Iacono, G., additional, Abate, A., additional, Pastorino, S., additional, Pescio, M.C., additional, Anserini, P., additional, and Del Mastro, L., additional

Published
2017
Full Text
View/download PDF

44. 186P - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial

Author

Conte, B., Bruzzone, M., Lambertini, M., Poggio, F., Blondeaux, E., De Laurentiis, M., Valle, E., Cognetti, F., Nisticò, C., De Placido, S., Merlano, M.C., Gamucci, T., Montemurro, F., Ceppi, M., and Del Mastro, L.

Published
2019
Full Text
View/download PDF

45. Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study

Author

Levaggi, A., primary, Poggio, F., additional, Lambertini, M., additional, D'Alonzo, A., additional, Giraudi, S., additional, Bighin, C., additional, Blondeaux, E., additional, Pastorino, S., additional, Abate, A., additional, Iacono, G., additional, Vaglica, M., additional, Conte, B., additional, Pronzato, P., additional, and Del Mastro, L., additional

Published
2016
Full Text
View/download PDF

46. Dose-dense adjuvant chemotherapy, treatment-induced amenorrhea and overall survival in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase 3 studies

Author

Blondeaux, E., primary, Lambertini, M., additional, Ceppi, M., additional, Cognetti, F., additional, Cavazzini, G., additional, De Laurentiis, M., additional, De Placido, S., additional, Michelotti, A., additional, Bisagni, G., additional, Durando, A., additional, Valle, E., additional, Scotto, T., additional, De Censi, A., additional, Turletti, A., additional, Benasso, M., additional, Barni, S., additional, Montemurro, F., additional, Puglisi, F., additional, Bighin, C., additional, Bruzzi, P., additional, and Del Mastro, L., additional

Published
2016
Full Text
View/download PDF

47. TP53 germline mutation testing in early onset breast cancer

Author

Conte, B., primary, Varesco, L., additional, Iacono, G., additional, Poggio, F., additional, Blondeaux, E., additional, Levaggi, A., additional, D'Alonzo, A., additional, Bighin, C., additional, Giraudi, S., additional, Vaglica, M., additional, Pronzato, P., additional, and Del Mastro, L., additional

Published
2016
Full Text
View/download PDF

48. Concurrent versus sequential adjuvant chemo-endocrine therapy in early stage hormone receptor-positive breast cancer patients: a systematic review and meta-analysis

Author

Poggio, F., primary, Ceppi, M., additional, Lambertini, M., additional, Bruzzi, P., additional, Ugolini, D., additional, Bighin, C., additional, Levaggi, A., additional, Giraudi, S., additional, D'alonzo, A., additional, Vaglica, M., additional, Blondeaux, E., additional, Conte, B., additional, Sertoli, M.R., additional, and Pronzato, P., additional

Published
2016
Full Text
View/download PDF

49. Dose-dence adjuvant chemotherapy in early breast cancer: the results of 15 years of follow-up

Author

Giraudi, S., primary, Cavazzini, M.G., additional, Michelotti, A., additional, De Censi, A., additional, Testore, F., additional, Benasso, M., additional, Sertoli, M.R., additional, Bighin, C., additional, Pastorino, S., additional, Levaggi, A., additional, D'Alonzo, A., additional, Lambertini, M., additional, Poggio, F., additional, Blondeaux, E., additional, Conte, B., additional, Pronzato, P., additional, and Del Mastro, L., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results